Non-alcoholic fatty liver disease risk with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes: a nationwide nested case–control study
GLP-1RA and SGLT2i therapies in type 2 diabetes patients might prevent NAFLD/NASH development, with a significantly lower risk related to greater treatment exposure.
Authors
- Shihchen Kuo (ORCID: https://orcid.org/0000-0001-6207-8792)
- Chun-Ting Yang (ORCID: https://orcid.org/0000-0002-7667-244X)
- Feng‐Chih Kuo (ORCID: https://orcid.org/0000-0001-5205-8333)
- Huang‐Tz Ou (ORCID: https://orcid.org/0000-0002-5475-7848)
- Chenyi Yang (ORCID: https://orcid.org/0000-0003-1126-7459)
- Kai-Cheng Chang
Institutions
- University of Michigan (US)
- Linkou Chang Gung Memorial Hospital (TW)
- National Cheng Kung University Hospital (TW)
- National Cheng Kung University (TW)
Publication Details
- Journal
- Cardiovascular Diabetology
- Published
- 2024-10-17
- DOI
- https://doi.org/10.1186/s12933-024-02461-2
- Citations
- 12
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.64
Funders
- Chang Gung Medical Foundation
- Ministry of Science and Technology, Taiwan